Results 41 to 50 of about 16,650 (226)

A Co-Occurrence of Serologically Proven Myasthenia Gravis and Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome

Case Reports in Neurological Medicine, 2019
We report on a co-occurrence case of ocular myasthenia gravis with exacerbation leading to myasthenic crisis in addition to pharyngeal-cervical-brachial variant of Guillain–Barré syndrome in a patient with severe oropharyngeal dysphagia and acute ...
Stacey Ho, Antonio Liu
doaj   +1 more source

Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients‐A Population‐Based, Matched Case–Control Study

Muscle &Nerve, Volume 73, Issue 6, Page 1016-1024, June 2026.
ABSTRACT Introduction/Aims Myasthenia gravis (MG) is associated with thymic neoplasms. However, an increased prevalence of extrathymic neoplasms has also been reported. This study aimed to evaluate the rates of malignancy in MG patients while accounting for risk factors such as disease characteristics and immunomodulatory treatments.
Keshet Pardo, Tasneem Kab, Mark A. Hellmann, Itay Lotan, Tzippy Shochat, Nadav Loebl, Bar Yacobi, Yitzhak Friedman, Leor Perl, Nitai Shimon, Yiska Loewenberg Weisband, Liya Bieber, Eitan Auriel, Adi Wilf‐Yarkoni   +13 more
wiley   +1 more source

Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System

Cancer Medicine, 2023
Objective To evaluate the risk of myasthenia gravis (MG) associated with immune checkpoint inhibitors (ICI). Methods Adverse event (AE) reports related to MG, myasthenic syndrome, and MG crisis for durvalumab, atezolizumab, pembrolizumab, nivolumab ...
Qingli Kong, Hui Wang, Xiaolei Ren, Yue Zhuo, Jing Peng   +4 more
doaj   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Lambert-Eaton Syndrome in Children

Pediatric Neurology Briefs, 2014
Investigators from Boston Children's Hospital; the Lahey Clinic, Burlington, MA; and Ohio State University, report 3 children presenting between ages 9 and 10 years with proximal lower extremity weakness with areflexia and low-amplitude compound muscle ...
J Gordon Millichap, John J Millichap
doaj   +1 more source

Structural Lung Disease in Children and Adolescents With Severe Neurological Disorders

Pediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Background and Objective Children with severe neurological disorders are at risk of secondary respiratory morbidity due to impaired airway clearance and dysphagia, but systematic data on structural lung changes remain scarce. Methods We retrospectively analyzed all clinically indicated chest CT examinations at a tertiary care center (2015–2025)
Daniel A. F. Bernard, Cathrin Dahl, Luca Salhöfer, Anna Pauly, Mathis Steindor, Margarete Olivier, Ulrike Schara‐Schmidt, Matthias Welsner, Bernd Schweiger, Sebastian Zensen, Marcel A. Drews, Johannes Haubold, Michael Forsting, Lale Umutlu, Marcel Opitz, Florian Stehling   +15 more
wiley   +1 more source

Congenital Myasthenic Syndrome and AChR Mutation

Pediatric Neurology Briefs, 2000
A 20-year-old woman from a consanguineous Moroccan marriage, with progressive muscle weakness noted from 2 years of age and evaluated at the University of Bonn, Germany, was found to have congenital myasthenic syndrome (CMS) due to homozygosity of the ...
J Gordon Millichap
doaj   +1 more source

Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study

European Journal of Neurology, Volume 33, Issue 6, June 2026.
In a cohort of 2043 patients treated with immune checkpoint inhibitors (ICI), severe neurological immune‐related adverse events (n‐irAEs) occurred in 0.5% of cases. These events predominantly involved the peripheral nervous system (PNS) and showed variable onset.
Anna Grisold, Angelika M. Starzer, Sara Silvaieh, Martin Krenn, Marie‐Bernadette Aretin, Manuela Schmidinger, Julia M. Ressler, Stephan Polterauer, Thomas Berger, Matthias Preusser, Anna S. Berghoff   +10 more
wiley   +1 more source

Adverse Drug Reaction Study of Botulinum Toxin‐A in the Real World

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Background Despite the increasing use of botulinum toxin type A (BoNT‐A) in aesthetic and therapeutic applications, its real‐world adverse drug reaction (ADR) profile remains incompletely characterized. Current evidence relies largely on small‐scale clinical observations rather than large, systematic analyses.
Jiaxu Gu, Yue Sun, Kexin Chen, Jieyi Wang, Bingcheng Lu, Hongqiang Xie, Xiaoming Liu, Cong Huang, Xingling Jian, Bo Yu   +9 more
wiley   +1 more source

Moderate phenotype of a congenital myasthenic syndrome type 19 caused by mutation of the COL13A1 gene: a case report

Journal of Medical Case Reports, 2022
Background Congenital myasthenic syndromes caused by mutations in the COL13A1 gene are very rare and have a phenotype described as severe. We present the first case of congenital myasthenic syndrome described in Algeria and the Maghreb with a new ...
Mohamed Islam Kediha, Meriem Tazir, Damien Sternberg, Bruno Eymard, Lamia Alipacha   +4 more
doaj   +1 more source